---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034903"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:44:34.129990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q3 net loss $6.3M ($0.31/sh); BARDA contract terminated; Mpox vaccine accelerated

## Summary
- Net loss of $6.3M vs $5.8M in Q3 2024; per-share loss improved to $0.31 from $0.91 due to share count change.
- Revenue fell to $0 as BARDA terminated Project NextGen contract for convenience in April 2025, compared to $2.8M in Q3 2024.
- Cash $5.0M at Sep 30, 2025, down from $5.5M at Dec 31, 2024; burn rate continues.
- GEO-MVA accelerated amid global Mpox emergency; EMA supports streamlined regulatory pathway.
- GEO-CM04S1 met primary endpoint in CLL trial; Gedeptin expanding into new solid tumor indications.

## SEC filing metadata
- accession: 0001437749-25-034903
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774925034903/0001437749-25-034903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774925034903/govx20251112_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034903
- JSON: https://secwatch.observer/filing/0001437749-25-034903.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.